A5076696174- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Gallbladder and Bile Duct Disorders
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cancer Mechanisms and Therapy
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Liver Disease Diagnosis and Treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Neuroblastoma Research and Treatments
- Gastric Cancer Management and Outcomes
- Cancer, Lipids, and Metabolism
- Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Hepatitis C virus research
- Cancer, Hypoxia, and Metabolism
- Palliative Care and End-of-Life Issues
- Liver physiology and pathology
- Multiple and Secondary Primary Cancers
- Peptidase Inhibition and Analysis
- Oral and gingival health research
National Cancer Center
2016-2025
Tokyo National Hospital
2015-2025
National Cancer Center Hospital East
2015-2024
National Cancer Centre Japan
2005-2023
Japan Cancer Society
2022
Kyorin University
2009-2018
Kanagawa Cancer Center
2004-2018
Kanagawa Prefectural Hospital Organization
2018
Alphabet (United States)
2017
Osaka International Cancer Institute
2011-2015
Everolimus, an oral inhibitor of mammalian target rapamycin (mTOR), has shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, two phase 2 studies. We evaluated the agent a prospective, randomized, 3 study.
PURPOSE The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC). We report results from a phase Ib study plus pembrolizumab (an anti–PD-1 antibody) unresectable HCC (uHCC). PATIENTS AND METHODS In this open-label multicenter study, patients uHCC received (bodyweight ≥ 60 kg, 12 mg; < 8 mg) orally daily and...
A British randomised study of gemcitabine plus cisplatin (GC) combination showed promising results in biliary tract cancer (BTC) patients. In our study, we evaluated the efficacy and safety this compared with alone (G) Japanese BTC
BACKGROUND: Patients with advanced biliary tract cancer have a poor prognosis, and first-line standard of care (gemcitabine plus cisplatin) has remained unchanged for more than 10 years. The TOPAZ-1 trial evaluated durvalumab chemotherapy patients cancer. METHODS: In this double-blind, placebo-controlled, phase 3 study, we randomly assigned previously untreated unresectable or metastatic recurrent disease 1:1 to receive placebo in combination gemcitabine cisplatin up eight cycles, followed...
NK911 is a novel supramolecular nanocarrier designed for the enhanced delivery of doxorubicin (DXR) and one successful polymer micelle systems to exhibit an efficient accumulation in solid tumours mice. The purpose this study was define maximum-tolerated dose (MTD) dose-limiting toxicities (DLTs) evaluate its pharmacokinetic profile man. given intravenously patients with every 3 weeks using infusion pump at rate 10 mg DXR equivalent min−1. starting 6 m−2, escalated according accelerated...
Purpose The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority gemcitabine plus compared with respect overall survival. Patients Methods participants were chemotherapy-naive patients locally advanced or metastatic pancreatic cancer. randomly assigned receive only (1,000 mg/m 2 on days 1, 8, 15 a 28-day cycle), (80, 100, 120 mg/d according body-surface area 1 through 28 42-day (gemcitabine 1,000 8 60, 80, 100 14 21-day cycle). Results In total...
This trial compared the efficacy and safety of transarterial chemoembolisation (TACE) plus sorafenib with TACE alone using a newly established TACE-specific endpoint pre-treatment before initial TACE.Patients unresectable hepatocellular carcinoma (HCC) were randomised to (n=80) or (n=76). Patients in combination group received 400 mg once daily for 2-3 weeks TACE, followed by 800 during on-demand conventional sessions until time untreatable (unTACEable) progression (TTUP), defined as tumour...
Cholangiocarcinoma is an intractable cancer, with limited therapeutic options, in which the molecular mechanisms underlying tumor development remain poorly understood. Identification of a novel driver oncogene and applying it to targeted therapies for molecularly defined cancers might lead improvements outcome patients. We performed massively parallel whole transcriptome sequencing eight specimens from cholangiocarcinoma patients without KRAS/BRAF/ROS1 alterations identified two fusion...
Since 1981, the Japan Pancreas Society has been hosting a nationwide pancreatic cancer registry. To commemorate its 30th anniversary, we review history and latest achievement.During 3 decades, more than 350 leading institutions in contributed voluntarily to register periodic follow-up. The registry was modified protect privacy by encrypting hash algorithm.From 1981 2007, 32,619 cumulative records were analyzed. overall survival of invasive improved significantly. More patients with earlier...
This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 as monotherapies in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring single, priming dose of (ClinicalTrials.gov identifier: NCT02519348).Patients HCC who had progressed on, were intolerant to, or refused sorafenib randomly assigned to receive T300 + D (tremelimumab 300 mg...
Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1-3, fibroblast 1-4, platelet-derived alpha, RET, and KIT. This phase 2, single-arm, open-label multicenter study evaluated lenvatinib in advanced hepatocellular carcinoma (HCC).Patients with histologically/clinically confirmed HCC who did not qualify for surgical resection or local therapies received at a dosage 12 mg once daily (QD) 28-day cycles. The primary efficacy endpoint was time to progression (TTP) per...